脾肺双补合剂联合细菌溶解产物胶囊治疗慢性阻塞性肺疾病稳定期患者疗效观察  

Clinical effect of Pifei Shuangbu mixtures combined with bacterial lysate capsules in the treatment of patients with stable chronic obstructive pulmonary disease

作　　者：宋本艳 孙兰 胡强 SONG Benyan;SUN Lan;HU Qiang(Department of Respiratory and Critical Care Medicine,the Affiliated Hospital of Panzhihua University,Panzhihua 617000,Sichuan Province,China)

机构地区：[1]攀枝花学院附属医院呼吸与危重症医学科,四川攀枝花617000

出　　处：《新乡医学院学报》2025年第5期369-378,共10页Journal of Xinxiang Medical University

基　　金：四川省中医药管理局科研专项面上计划项目(编号:2023MS104)。

摘　　要：目的观察脾肺双补合剂联合细菌溶解产物胶囊治疗慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效。方法选择2022年6月至2023年12月于攀枝花学院附属医院呼吸与危重症医学科就诊的120例COPD稳定期患者为研究对象。采用随机数字表法将患者分为对照组、细菌溶解产物胶囊组、脾肺双补合剂组和联合组,每组30例。对照组患者吸入布地奈德福莫特罗粉,细菌溶解产物胶囊组患者在对照组基础上口服细菌溶解产物胶囊,脾肺双补合剂组患者在对照组基础口服脾肺双补合剂,联合组患者在对照组基础上口服菌溶解产物胶囊和脾肺双补合剂,4组患者均治疗3个月。比较各组患者的临床疗效、不良反应。干预前和干预6个月后,评估各组患者的中医证候积分和肺功能;采用慢性阻塞性肺疾病评估测试评分(CAT)和St Georges呼吸问卷(SGRQ)对患者的病情及健康状态进行评估;采用流式细胞术检测4组患者外周血中T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))水平,并计算CD4^(+)/CD8^(+);采用酶联免疫吸附法检测4组患者血清中炎症因子白细胞介素(IL)-5、IL-17、肿瘤坏死因子-α(TNF-α)水平;检测各组患者粪便中双歧杆菌、乳酸杆菌以及肠球菌的含量。结果对照组、细菌溶解产物胶囊组、脾肺双补合剂组、联合组患者的总有效率分别为73.33%(22/30)、80.00%(24/30)、83.33%(25/30)、93.33%(28/30)。细菌溶解产物胶囊组、脾肺双补合剂组、联合组患者的总有效率均显著高于对照组(χ^(2)=22.526、20.041、24.320,P<0.05);细菌溶解产物胶囊组与脾肺双补合剂组患者的总有效率比较差异无统计学意义(χ^(2)=12.337,P>0.05);联合组患者的总有效率显著高于细菌溶解产物胶囊组和脾肺双补合剂组(χ^(2)=10.251、8.126,P<0.05)。4组患者干预后6个月的咳喘无力、呼吸气促、自汗畏风和少气懒言中医证候积分均显著低于干预前(P<0.05)。干预�Objective To investigate the clinical efficacy of Pifei Shuangbu mixtures combined with bacterial lysate capsules for the treatment of patients with stable chronic obstructive pulmonary disease(COPD).Methods A total of 120 patients with stable COPD treated at the Department of Respiratory and Critical Care Medicine,the Affiliated Hospital of Panzhihua University from June 2022 to December 2023 were included in the study.They were divided into a control group,a bacterial lysate capsule group,a Pifei Shuangbu mixture group and a combination group by the random number table method,with 30 cases in each group.Patients in the control group inhaled only budesonide formoterol powder.In addition to budesonide formoterol powder,patients in the bacterial lysate capsule,Pifei Shuangbu mixture and combination groups were also treated with oral bacterial lysate capsules,Pifei Shuangbu mixtures,and bacterial lysate capsules combined with Pifei Shuangbu mixtures,respectively.All the patients were treated for 3 months,and then the clinical efficacy and adverse reactions were compared among groups.The traditional Chinese medicine(TCM)syndrome scores and lung function of the patients in each group were evaluated before intervention and 6 months after intervention.The COPD assessment test scores(CAT)and St Georges respiratory questionnaire(SGRQ)were used to evaluate the condition and health status of the patients.The levels of T lymphocyte subsets(CD3^(+),CD4^(+),and CD8^(+))in the peripheral blood of the four groups of patients were detected by flow cytometry,and the CD4^(+)/CD8^(+)ratio was calculated.The levels of serum inflammatory factors including interleukin(IL)-5,IL-17,and tumor necrosis factor-α(TNF-α)in the four groups of patients were detected by enzyme-linked immunosorbent assay.The content of bifidobacteria,lactobacilli,and enterococci in the feces of the patients in each group was measured.Results The total effective rates of patients in the control,bacterial lysate capsule,Pifei Shuangbu mixture,and combination gro

关 键 词：慢性阻塞性肺疾病 脾肺双补合剂 细菌溶解产物胶囊 肺功能 免疫功能 炎症因子 临床疗效 

分 类 号：R563[医药卫生—呼吸系统]